176 related articles for article (PubMed ID: 31540979)
1. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.
Lohrmann C; O'Reilly EM; O'Donoghue JA; Pandit-Taskar N; Carrasquillo JA; Lyashchenko SK; Ruan S; Teng R; Scholz W; Maffuid PW; Lewis JS; Weber WA
Clin Cancer Res; 2019 Dec; 25(23):7014-7023. PubMed ID: 31540979
[TBL] [Abstract][Full Text] [Related]
2. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
Escorcia FE; Steckler JM; Abdel-Atti D; Price EW; Carlin SD; Scholz WW; Lewis JS; Houghton JL
Mol Imaging Biol; 2018 Oct; 20(5):808-815. PubMed ID: 29508263
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with
Houghton JL; Abdel-Atti D; Scholz WW; Lewis JS
Mol Pharm; 2017 Mar; 14(3):908-915. PubMed ID: 28191976
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
Houghton JL; Zeglis BM; Abdel-Atti D; Sawada R; Scholz WW; Lewis JS
J Nucl Med; 2016 Mar; 57(3):453-9. PubMed ID: 26471693
[TBL] [Abstract][Full Text] [Related]
7. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of Pancreatic Tumors with
Sobol NB; Korsen JA; Younes A; Edwards KJ; Lewis JS
Mol Imaging Biol; 2021 Feb; 23(1):84-94. PubMed ID: 32909244
[TBL] [Abstract][Full Text] [Related]
9. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
10. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
11. Associations of volumetric whole-body
Araç E; Can C; Kömek H
Hell J Nucl Med; 2020; 23(1):40-47. PubMed ID: 32361716
[TBL] [Abstract][Full Text] [Related]
12. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
14. The value of
Wang S; Shi H; Yang F; Teng X; Jiang B
Abdom Radiol (NY); 2019 Dec; 44(12):4057-4062. PubMed ID: 31570958
[TBL] [Abstract][Full Text] [Related]
15. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
17. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
Viola-Villegas NT; Rice SL; Carlin S; Wu X; Evans MJ; Sevak KK; Drobjnak M; Ragupathi G; Sawada R; Scholz WW; Livingston PO; Lewis JS
J Nucl Med; 2013 Nov; 54(11):1876-82. PubMed ID: 24029655
[TBL] [Abstract][Full Text] [Related]
18. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
[TBL] [Abstract][Full Text] [Related]
19. Clinical Translation of a
Feng X; Wang Y; Lu D; Xu X; Zhou X; Zhang H; Zhang T; Zhu H; Yang Z; Wang F; Li N; Liu Z
J Nucl Med; 2020 Oct; 61(10):1461-1467. PubMed ID: 32086242
[TBL] [Abstract][Full Text] [Related]
20. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles.
Girgis MD; Federman N; Rochefort MM; McCabe KE; Wu AM; Nagy JO; Denny C; Tomlinson JS
J Surg Res; 2013 Nov; 185(1):45-55. PubMed ID: 23827791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
